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Abstract
Background: There is real need to change how we do some of our clinical trials, as currently the testing and develop-
ment process is too slow, too costly and too failure-prone - often we find that a new treatment is no better than the
current standard.
Purpose and Methods: Much of the focus on the development and testing pathway has been in improving the design
of phase I and II trials. In this paper we present examples of new methods for improving the design of phase III trials
(and the necessary lead up to them) as they are the most time-consuming and expensive part of the pathway. Key to all
these methods is the aim to test many treatments and/or pose many therapeutic questions within one protocol.
Results: The four principles underlying these solutions are:
1) evaluate many primary hypotheses/treatments within the same protocol
2) if there is a pilot/feasibility/phase II part of the process, aim to have a seamless run through to the phase III part of the
process
3) whenever possible and appropriate, conduct an adaptive trial, with the adaptations being major ones such as adding
or dropping arms
4) in situations where we are considering subgroups of a specific disease, often biomarker-defined, aim to include ques-
tions testing new treatments in all (or most) subgroups, using an adaptive approach.
We present some examples of the application of these principles to particular areas, and show how they have led us to
develop and launch multi-arm, multi-stage platform, umbrella and basket protocols: STAMPEDE, TRUNCATE-TB,
FOCUS-4 and Add-Aspirin.
Limitations: There are clear challenges when embarking on such protocols. They include the need: to garner large
scale collaboration bringing large parts of the research community together; to obtain significant and long-term funding;
to obtain long term commitment from the key research leaders; to ensure that responsibilities (and also acclaim) are
shared as widely as possible; and to have operational structures and systems which allow the implementation of such
long-term adaptive protocols. These challenges need to be addressed when the protocol is at the design stage, as they
will need to be resolved before any funding is likely to be approved and released.
Conclusions: Through these designs our aim is to change the fundamental goal of a single clinical protocol from the
typical 2-arm randomised trial of ‘testing a new treatment’ to ‘testing many treatments and hence improving outcomes
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as rapidly as possible’. We are exploring opportunities to develop such protocols in areas such as Alzheimer’s disease,
multiple sclerosis, HIV prevention, hepatitis C and wound healing, to speed the process of testing new therapies, and
we urge others involved in the design of new trials to follow this way of thinking.
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Introduction
There are a number of challenges in the development
and testing of new therapies. These include the fol-
lowing: (1) the development and testing process is too
slow, takes too long and too often shows that new is
not better than our current standard;1 (2) in some dis-
eases, the number of new therapies and combinations
of therapies demanding evaluation is large, much
larger than it has been for many years, due to a revo-
lution in biology resulting in a rational selection and
synthesis of agents directed at specific targets; (3)
some diseases are being classified into smaller subsets,
often using molecular characterisation; and (4) the
process of developing and starting a new trial is costly
and time-consuming, and as a consequence, there is
often too long a gap between phase II and phase III
trials, and also between separate phase III trials, par-
ticularly in the academic world.
Much has been written about some of these problems
and a number of solutions have been proposed.
However, almost all of these solutions have been pro-
posed for the phase I and particularly phase II part of
the testing process.2–4 In this article, we present some
solutions in phase III testing, with the aim of speeding
this part of the process, and also increasing the chance,
within an individual protocol, of reliably identifying at
least one new treatment that is superior to the control
treatment.5 The rationale for this focus is that the phase
III part is usually the longest and the most expensive part
of the testing process. The details of some of these solu-
tions have been described elsewhere.6–8 Here, we give a
brief summary and examples. The four principles under-
lying these solutions are as follows:
1. Evaluate many primary hypotheses/treatments
within the same protocol; this maximises the
chance of identifying a new treatment which is bet-
ter than the current standard;5 aim to make the
research arms as different as possible from each
other;
2. If there is a pilot/feasibility/phase II part of the
process, aim to have a seamless run through to the
phase III part and, if at all possible, include in the
phase III evaluation the information from patients
in the early evaluation;
3. Whenever possible and appropriate, conduct an
adaptive trial, with the adaptations being major
ones, such as ceasing randomisation to a research
arm or introducing new research arms;
4. In situations where we are considering subgroups
of a specific disease, often biomarker-defined, aim
to include questions testing new treatments in all
(or most) subgroups, using an adaptive approach
to allow (1) refinement of the subgroups, (2) intro-
duction of new subgroups, (3) the ability to stop
testing specific treatments and introduce new treat-
ments and (4) evaluation of the link between the
biomarker and that treatment.
Below we present some examples of the application
of these principles to particular areas and show how
they have led us to develop and launch multi-arm,
multi-stage platform, umbrella and basket protocols.
We also address the major statistical issue: when there
are many primary hypotheses, the probability of mak-
ing at least one false positive discovery when multiple
hypothesis tests are performed, and the null hypothesis
is true. This is called the family-wise error rate
(FWER). We also consider the implication of adding
arms.
Multi-arm, multi-stage platform protocols
Systemic Therapy in Advancing or Metastatic
Prostate Cancer: Evaluation of Drug Efficacy
(launched in 2005)
Prostate cancer is one of the most common cancers
globally, accounting for 1.1 million cases and 0.3 mil-
lion deaths each year.9 A substantial proportion of
these men are diagnosed with, or progress to, high-risk
prostate cancer. This includes men whose cancer has
already spread to other parts of the body, usually the
bones, or which is restricted to the pelvis but has other
adverse prognostic features. These patients are often
referred to as having ‘hormone sensitive disease’. In the
early 2000s, when STAMPEDE (Systemic Therapy in
Advancing or Metastatic Prostate Cancer: Evaluation
of Drug Efficacy) was being designed, the standard of
care for these men was a treatment which had been
introduced more than 40 years before – long-term hor-
mone therapy; aiming to control the disease by reduc-
ing the level of the male hormone, testosterone. Despite
this treatment, outcomes for these men remained poor,
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with a 5-year survival of 40% which had not changed
over these 40 years.
At the time of designing STAMPEDE (www.stam-
pedetrial.org), there were a number of treatments
showing promise in later stages of prostate cancer and,
working with clinical experts in the United Kingdom
(the National Cancer Research Institute Prostate
Cancer Clinical Studies Group and its predecessor
committees), these were systematically considered.
Rather than, somewhat arbitrarily, selecting a single
treatment in which to invest all efforts and resources, it
was agreed that it would be better to develop a multi-
arm, multi-stage platform clinical protocol so that a
small number of the most promising of these treat-
ments could be tested simultaneously. A key criterion
in selecting agents to test was their mode of action,
with the aim of choosing treatments which had differ-
ing modes of action. There was a greater chance in
improving outcomes if, in the different research arms,
quite different (rather than similar) treatments were
tested. Furthermore, treatment arms that were success-
ful could then potentially be combined to achieve even
greater improvements in survival. In this sense, the new
treatments would not be considered to be competing
Figure 1. STAMPEDE protocol (a) at initiation (figure produced in October 2005) and (b) adapted protocol from 2005 to 2024
(figure produced in September 2016).
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with each other. Ultimately, three new treatments were
selected: a third-generation bisphosphonate (zoledronic
acid, made by Novartis), a taxane-based chemotherapy
(docetaxel, Sanofi–Aventis) and an oral Cox-2 inhibitor
(celecoxib, Pfizer). Pre-clinical data were also available
to support inclusion of two combinations of pairs of
these agents. Therefore, a protocol with one control
arm (standard of care) and five research arms was
launched, each of these five arms supplementing the
standard of care with one or two of these agents.
Figure 1(a) shows the design of the protocol at initia-
tion in 2005. One way of viewing this protocol is that it
is just a series of two-arm trials, with each research arm
being compared against a (common) control arm for
overall survival, all of which happen to be in the same
protocol.
Calculations showed that to answer these five
research questions, it would take us approximately
7 years to randomise up to 3500 patients (with a fur-
ther minimum follow-up of 3 years) to provide a fully
reliable answer on the primary outcome measure, over-
all survival. This was clearly ambitious and involved a
larger number of patients than any previous trial in
prostate cancer had targeted. To help mitigate this
challenge and recognising the fact that it was very
unlikely that all the new treatment regimens would be
effective, a lack of benefit analysis at a number of
stages was planned, comparing each research arm
against the control arm in terms of the intermediate
outcome measure of failure-free survival. For a multi-
arm trial with k research treatments the optimal rando-
misation ratio between the control and each research
arm is k1/2.10 In STAMPEDE, we started with five
research arms; therefore, as an approximation, we ran-
domised patients in the ratio of 2:1:1:1:1:1 control to
each research arm.
The biology of the disease and the drugs being tested
meant that it was anticipated that any advantage in
survival would be preceded by a reduction in markers
of prostate cancer activity. Therefore, an intermediate
outcome measure of failure-free survival was defined,
primarily driven by rises in prostate-specific antigen (a
blood marker for prostate cancer), assuming that any
advantage in overall survival would be preceded by a
benefit in failure-free survival; if there was little or no
benefit in failure-free survival there was very unlikely
to be a benefit in overall survival. Interim analyses were
therefore set up to consider failure-free survival with
the aim that recruitment could stop early to any
research arm that did not show sufficient activity (com-
pared to the control arm) on this interim outcome mea-
sure, rather than waiting for overall survival data. Note
that it was not assumed that a benefit in failure-free
survival would necessarily translate to an advantage in
overall survival. Full details of the design of the trial
are given in the article by Sydes et al.11
Given the ambitious nature of the design and the fact
that some of these regimens, particularly the combina-
tions, were being used for the first time in this setting,
the trial was initially started in just a few sites in a pilot
stage. The Independent Data Monitoring Committee
monitored the first 210 patients to confirm the safety of
all the research arms before the trial was opened to all
sites. Ultimately, more than 100 sites in the United
Kingdom and 7 sites in Switzerland have randomised at
least one patient to the trial.
In practice, 3585 patients were recruited to these six
arms. Randomisation to two of the research arms, both
of those containing celecoxib, was stopped on the
advice of the Independent Data Monitoring Committee
at the second interim activity analysis in April 2011,
and data supporting this decision were published.12
The other three research arms successfully recruited
past all three interim activity stages, and recruitment
was completed in March 2013.
All randomised patients were followed until the pre-
planned number of deaths (approximately 400 in the
control arm) were observed in 2016.13 These data,
together with other relevant randomised data,14 showed
clear evidence of a survival advantage of the che-
motherapy drug docetaxel when added to standard of
care. Practice in many countries, including the United
Kingdom, changed rapidly afterwards to allow che-
motherapy in this population of patients. Adding zole-
dronic acid to standard of care showed no evidence of a
survival advantage, while the combination of docetaxel
and zoledronic acid did show evidence of a survival
advantage; there was no evidence that this was better
than adding just docetaxel alone.
As a consequence of these results (and the contem-
poraneous meta-analysis including these results14) the
design of STAMPEDE was changed immediately in
January 2016 to allow patients to receive the drug doce-
taxel as part of their standard of care. In recent months,
four-fifths of metastatic patients have planned doce-
taxel as part of their standard care. STAMPEDE may
be a unique trial in which the standard of care for the
trial has been changed as a consequence of results from
the trial itself.
Adding arms to STAMPEDE
In 2010, 5 years into STAMPEDE recruitment, the
drug abiraterone was showing very promising results in
patients with prostate cancer at more advanced stages
than those entering STAMPEDE – that is, in patients
with hormone refractory disease.15 At this time, there
were three realistic options: (a) choose to not test abira-
terone in this setting and leave its assessment to others;
(b) open a competing trial, which could hamper recruit-
ment to both STAMPEDE and the abiraterone trial
and mean that more men were allocated to a control
arm across the two trials; or (c) incorporate abiraterone
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as a new research arm within STAMPEDE. The last of
these options is clearly the most efficient in terms of the
total numbers of patients required, recruitment of
patients, time taken to initiate and approve a protocol,
the workload for initiation of sites, and overall costs.
To incorporate abiraterone involved a new industry
partner, Janssen. This new arm, and the ‘continued’ con-
trol arm, was planned to recruit to a specific target num-
ber of patients during and after the recruitment period
for the original research arms. Patients in this new
research arm are only compared with contempora-
neously randomised controls. The abiraterone research
arm opened to recruitment in November 2011 (4 years
before the docetaxel results emerged) with an initial tar-
get of 1500 patients. It was added through a protocol
amendment (and not the development and approval of a
whole new trial), providing huge efficiency and speed. It
closed to recruitment 9 months earlier than planned,
despite an expanded target of 1800 patients, with 1917
patients recruited by January 2014 (again, before the pri-
mary results of the original comparisons were mature).
This showed clearly that adding an arm into an ongoing
assessment could speed the initiation of, and recruitment
to, a new comparison. Results from this comparison
have recently been presented and have shown that add-
ing abiraterone improves overall survival, the second
positive result to emerge from STAMPEDE.16
The clear success of adding the abiraterone arm sub-
sequently led to the incorporation of three additional
research arms into STAMPEDE (Figure 1(b)). Each of
these arms has been developed with the traditional
approach in terms of scientific rigour. In particular, a
persuasive scientific case has to be made, and successful
independent, international peer-review, as well as fund-
ing, has to be obtained. One helpful way to think about
these new research arms is that a new comparison is
being launched, which has been added to the
STAMPEDE protocol. The three arms which have
been added are (a) the addition of radiotherapy to the
prostate in the subgroup of men whose disease had
already spread, (b) the combination of abiraterone and
enzalutamide (bringing a further drug company into
STAMPEDE – Astellas) and (c) the addition of metfor-
min, seeking to repurpose a drug widely used to man-
age diabetes. A further two research arms will be
initiated in 2017. Figure 1(b) shows the history of
initiation, recruitment and analysis activities to the pro-
tocol to 2024.11,17,18
FWER and adding arms
The FWER for the three original research arms that
reached their planned target was 6.75%.13,19 For the
added research arms, ongoing work has shown that the
implications for the FWER are dependent on the pro-
portion of overlap in control arm patients between the
research arms. If there was overlap of only one patient
in the control groups for two different research arms,
this would be (almost) like doing two independent trials
with one common patient. In this instance, there would
be no practical change to the type 1 error for these two
comparisons.
In Figure 1(b), we can observe that the only signifi-
cant overlap of control arm patients is between research
arms H and J, where some allowance for multiple test-
ing may need to be considered – for the remaining new
research arms there is relatively little overlap and thus
they can be regarded, in practical terms, as independent
trials. This is confirmed, for example, by calculating the
correlation between the test statistics comparing arm G
with contemporaneous controls and the original six
arms with their contemporaneous controls. The esti-
mated correlation between these test statistics is 0.12 –
emphasising the lack of overlap and their relative
independence.
By 2020, STAMPEDE will have answered eight
major questions in the 15 years since the first patient
was entered; a series of sequential two-arm trials would
have taken many tens of years longer to achieve this.
Results from arms B, C, D, E, F and G have already
been reported and standard of care has changed as a
consequence (Figure 1(b)).12,13,16,20 In the years 2015–
2020, STAMPEDE will have produced a major new
result on average every 18 months. With this approach,
there is a real opportunity to improve outcomes for
patients with hormone sensitive prostate cancer in a
major way over this period. Future plans for
STAMPEDE include testing further treatments, partic-
ularly those which are targeted at specific groups of
patients in whom they are likely to be most effective.
Two-month Regimens Using Novel Combinations to
Augment Treatment Effectiveness for drug-sensitive–
Tuberculosis (launched in 2017)
Tuberculosis (TB) is one of the oldest known diseases
and was considered to have been brought under control
with the introduction of very effective treatment more
than 30 years ago.21 Today TB kills more people than
any other single infectious disease and, in 2015 alone,
TB caused 1.8 million deaths. TB disproportionately
affects poorer communities; low-income countries that
represent only 42% of the world’s population account
for 65% of TB cases and 71% of deaths. The standard
length of treatment for the vast majority of patients
(with drug sensitive disease) is 6 months with a cocktail
of four drugs. In clinical trials, 95% of patients are
cured. However, in these trials, all patients are treated
and followed to a strict protocol and therapy given in
the clinic. In routine use, such close supervision is not
possible and adherence to treatment is consequently
poorer – some patients stop taking the medication when
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they feel better, often after a few months. As a result,
the observed cure rate is usually 85% or less.
A shorter treatment regimen that has better adher-
ence in routine use may provide better overall out-
comes, even if the efficacy might be slightly lower when
tested in a clinical trial. Reporting in 2014, three major
phase III randomised trials demonstrated unacceptable
relapse rates in excess of 10% in regimens of 4 months
in length (compared to the standard 6 months of treat-
ment), and pre-specified non-inferiority criteria were
not met. However, if a new treatment regimen is very
short, say 2 months duration, then a relapse rate of
10%, or even higher, might be acceptable, since patients
who experience a relapse after such treatment can, in
general, be treated successfully with 6 months of ther-
apy. Such a strategy may indeed be more successful
than a first-line treatment of 6 months of therapy
because trial results would more readily translate into
routine practice due to improved adherence. There may
be other benefits, in that a 2-month regimen would
likely be more cost-effective, more attractive to patients,
reduce the risk of toxicity and fit well with the initiation
of treatment for HIV (as many patients with TB will be
diagnosed with HIV at the same time).
There are a number of new and repurposed drugs in
clinical development leading to a large number of poten-
tial 3–4 drug combinations that could be combined to
form a 2- to 3-month first-line treatment strategy. Similar
to STAMPEDE, rather than choosing one regimen some-
what arbitrarily, the Two-month Regimens Using Novel
Combinations to Augment Treatment Effectiveness for
drug-sensitive–Tuberculosis (TRUNCATE-TB) trial is
evaluating, in the first instance, four novel 2- to 3-month
regimens using a multi-arm, multi-stage platform design
(www.sprinttb.org/theme-3-clinical-trials). Investigators
have used the best available evidence and expert opinion
to decide on the combination regimens that have the high-
est chance of success in a clinical trial. The process resulted
in four high-priority regimens that are included in the
TRUNCATE-TB trial, with further regimens identified
should the opportunity arise to initiate new arms (again a
process which has been successful in STAMPEDE).
TRUNCATE-TB is being conducted by hospitals in East
Asia and is a collaboration between the MRC Clinical
Trials Unit at UCL and the National University of
Singapore. Accrual will start in mid-2017.
The design of TRUNCATE-TB is shown in Figure
2, and details are given in the study by Papineni et al.22
In short, each research arm will be compared against
the control arm to assess whether it is non-inferior (by a
pre-specified amount) in terms of the proportion of
patients with an unsatisfactory clinical outcome at
96 weeks (approximately 2 years) from randomisation.
Two interim analyses are planned, and the final analysis
will be conducted with a one-sided 1.25% significance
level (using a Bonferroni correction and assuming that
two arms will reach the final stage) to maintain the
overall one-sided FWER at 2.5%.
Umbrella protocol: FOCUS4 (launched in 2014)
Oncology is in the vanguard of personalised or stratified
medicine and an area which requires new and more effi-
cient trial designs.23 One such design is FOCUS47
Figure 2. Protocol schema for TRUNCATE-TB.
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(www.focus4trial.org) (Figure 3). FOCUS4 is an
umbrella design aimed at to identifying effective treat-
ments in patients with metastatic colorectal cancer. An
umbrella protocol is one which aims to include patients
with a single disease divided into subsets, often with dif-
ferent therapies being explored in each of these subsets.
FOCUS4 stratifies all patients with metastatic color-
ectal cancer into a hierarchical structure of predomi-
nantly genetic mutations that are known to play an
important role in the tumour biology of advanced col-
orectal cancer. Within each of these strata, randomised
comparisons are opened to test therapies that have been
designed to target these specific molecular alterations.
Each trial is placebo-controlled whenever possible, and
each uses multi-stage methodology to test for drug
activity on progression-free survival at pre-defined time
points during each sub-trial. Each sub-trial has its own
control arm and has been designed, and will be ana-
lysed separately, meaning that there is no issue regard-
ing multiple testing.
The design of FOCUS4 follows seven specific
principles:7
1. Enables the testing of multiple treatment/biomar-
ker combinations at the same time;
2. Uses an enrichment strategy that, at first, only tests
the targeted treatment in the biomarker positive
group;
3. Uses randomised comparisons within each ther-
apy/biomarker evaluation to allow for any prog-
nostic effects of the biomarker (the magnitude of
which may often be uncertain);
4. Uses a multi-stage statistical design with pre-defined
interim analyses for assessment of drug activity such
that drugs failing to provide adequate levels of
activity are dropped, while more promising drugs
can move seamlessly from a phase II to a phase III
setting without having to start a new trial;
5. For treatment/biomarker combinations that are
demonstrating promising drug activity in early
interim analyses, the design allows testing of the
specificity of the biomarker by opening up trial
recruitment to patients who are negative for that
biomarker;
6. Allows new treatment/biomarker combinations to
be dropped, adapted or added to the umbrella pro-
tocol platform in response to an ever moving scien-
tific landscape. As these are essentially separate
sub-trials, this is not complex (in terms of the sta-
tistical design and operating characteristics);
7. Provides a clinical trial opportunity for all patients,
regardless of their biomarker status. Rare biomar-
kers can be evaluated in the platform alongside
more common ones, and patients whose tests have
shown no clear result for any biomarker can enter
a trial testing a non-stratified research question.
FOCUS4 opened to recruitment in January 2014
and is currently evaluating three treatments in four
biomarker-defined groups. One further treatment has
already been dropped due to lack of sufficient activity.
Over the period of the trial, it is hoped that at least six
new drugs will be evaluated with a number of them
advancing to both phase III testing and assessment of
biomarker specificity.
Basket protocol: Add-Aspirin (launched in 2015)
The re-evaluation of an already established medicine for a
new clinical indication, a process known as repurposing,
Figure 3. Protocol schema for FOCUS4.
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is a potentially attractive way to improve outcomes in
many diseases. With repurposed drugs, many traditional
aspects of the drug development pathway do not have to
be undertaken, speeding the pathway to ultimate phase
III testing. For example, some data on efficacy and safety
are often already available, typically through epidemiolo-
gical and/or post-marketing data. Similarly, their use and
co-administration with existing therapies is sometimes
known, and toxicity and interaction profiles may already
be established. Finally, and importantly, generic medicines
are often more readily available in resource-limited set-
tings, where much of the burden of some diseases is found
– for example, 70% of the new cancer patients are found
in the resource poor world. Effective repurposing of
drugs, therefore, offers the potential for a major impact
on a number of diseases worldwide.
In cancer, aspirin may be the exemplar of a repur-
posing agent – preclinical data over 40 years have
shown its anticancer properties and, in particular, the
potential to reduce the formation of metastases.24
Figure 4. Protocol schema for Add-Aspirin.
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Initial clinical investigation focussed on primary pre-
vention of cancer, particularly colorectal, and it is only
with the more recent evaluation of long-term cancer
outcomes from randomised trials in the prevention of
vascular disease that the full potential of aspirin as an
anticancer therapy has been recognised. In these trials,
allocation to aspirin resulted in individuals developing
fewer cancers across a range of tumour sites.
Individuals taking aspirin who did develop cancer were
less likely to have metastases at diagnosis and less likely
to develop them subsequently.25
This body of evidence has led to the development of
the Add-Aspirin trial – a basket protocol encompassing
four individually powered, randomised, double-blind,
phase III adjuvant studies in breast, colorectal, gastro-
oesophageal and prostate cancer (www.addaspirintria-
l.org). One definition of a basket protocol is one which
includes patients with many different diseases, but the
patients are linked because there is a treatment which
targets a pathway which is common to all these patients.
In the Add-Aspirin trial, all potential participants
have undergone primary potentially curative therapy
(surgery 6 adjuvant/neoadjuvant chemotherapy/radio-
therapy or primary chemoradiation). Following a run-
in phase where adherence and toxicity on aspirin are
assessed, participants are randomised to 100-mg
aspirin, 300-mg aspirin or matched placebo to be taken
daily for at least 5 years (Figure 4). Full details of the
protocol can be found in the paper by Coyle et al.8 In
brief, for each cancer type, the principal comparison is
(for both doses combined) of aspirin versus placebo. In
all those cancers showing a positive result, the groups
receiving 300 mg against 100 mg of aspirin will also be
compared. Since the latter comparison is a closed test,
conditional on seeing a positive result in the primary
comparison, there is no impact on the FWER. The trial
also has a very long-term co-primary outcome measure
of overall survival (analysed at approximately 15 years)
across the four tumour cohorts encompassing effects
on disease recurrence, potential vascular (and other)
benefits and second malignancies. This is important as
positive results across all four malignancies might sug-
gest the use of aspirin as an adjuvant treatment for
many other cancers not studied within the Add-Aspirin
protocol – it would be unrealistic to conduct an adju-
vant trial in all such malignancies. This analysis will be
performed with a more stringent significance level to
control the FWER across analyses to be 5% (two-
sided). Finally, in the colorectal cancer cohort, there
will be pre-planned and appropriately powered analysis
in the patients whose tumours show PIK3CA muta-
tion, whether or not the overall results in these groups
of patients are positive or not. There is some evidence
to suggest that individuals with PIK3CA mutation in
their tumour might benefit when others do not (or,
even when others do benefit, that these individuals
might benefit the most). The trial therefore potentially
answers many therapeutic questions beyond those spe-
cific to the four tumour types included.
Discussion
There is real need to change how we do some of our
clinical trials, as currently the testing and development
process is too slow, too costly and too failure-prone –
often we find that a new treatment is no better than the
current standard. Much of the focus on the develop-
ment and testing pathway, to date, has been in improv-
ing the design of early phase trials. In this article, we
have concentrated on new methods for improving the
design of late phase trials (and the necessary lead up to
them), as they are the most time-consuming and expen-
sive part of the pathway. Key to all these methods is
the aim of testing many treatments and/or posing many
therapeutic questions within one protocol together with
an adaptive approach allowing introduction of new
research questions as they arise.
The most mature example is STAMPEDE which
was launched in 2005. By 2020, the trial will have pro-
duced eight major results (arms B–J in Figure 1(b)).
Standard of care for these patients has already changed
as a result of findings from the trial, and the trial has
adapted to this changed standard of care. With more
traditional designs, a number of separate trials evaluat-
ing each of the new therapies might have been con-
ducted sequentially or, if running in parallel, would
have used separate control groups. Thus, it would have
taken many more decades and required many more
patients to achieve such outputs. STAMPEDE contin-
ues to recruit well, as do the two trials launched more
recently, FOCUS4 and Add-Aspirin. TRUNCATE-TB
will be launched in the summer of 2017.
There are nonetheless clear challenges when embark-
ing on such protocols. They include the need to garner
large-scale collaboration bringing large parts of the
research community together, to obtain significant and
long-term funding, to obtain long-term commitment
from the key research leaders, to ensure that responsi-
bilities (and also acclaim) are shared as widely as possi-
ble and to have operational structures and systems
which allow the implementation of such long-term
adaptive protocols. These challenges need to be
addressed when the protocol is at the design stage, as
they will need to be resolved before any funding is
likely to be approved and released.
A detailed discussion of the timing and frequency of
interim analyses is beyond the scope of this article.
However, it should be noted that the criteria for, and
implications of, stopping for lack of benefit are quite
different to stopping for overwhelming benefit. In the
former, the emphasis is usually on the current estimate
of the ‘treatment effect’ on an intermediate outcome
measure, and if it is small (or null/negative), then we
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may conclude the likelihood of a worthwhile treatment
effect on the primary outcome measure is also likely to
be small. Usually, stopping further randomisations to a
research arm for lack of benefit has no implications for
either the control arm or other research arms in the
trial. In contrast, stopping an arm for overwhelming
benefit usually focusses on the need for a small p value
for the ‘treatment effect’ on the primary outcome mea-
sure. Furthermore, stopping for an overwhelming bene-
fit has direct implications, for the control arm in
particular, and potentially all of the other research
arms. The designs above are themselves evolving and
will continue to do so, each using the platform that has
been developed to, for example, test further therapies
in subsets or the whole population, or by evaluating
the link between a biomarker and a treatment. For
example, STAMPEDE is developing randomised ques-
tions of targeted therapies for patients with specific
genetic mutations, taking aspects of the FOCUS4
design into its design. The Add-Aspirin protocol is
already doing the same and is also considering adding
further randomisations testing other repurposed thera-
pies, either by adding arms or by adding a factorial
randomisation. Software to aid the design of these
more complex studies is also being developed alongside
the trials themselves – for example, the Stata program
nstage for multi-arm, multi-stage designs26 and nbin-
stage for multi-arm, multi-stage trials with a binary
outcome (freely available from the Statistical Software
Components archive at www.repec.org). These will
support the development of such trials by other
research groups.
A question often posed is as follows: is there an opti-
mal number of arms for a multi-arm trial? The short
answer to this question has to be no, as perhaps the big-
gest drivers of the number of arms are the number of
patients available, the number of research treatments
that are ready and available for testing and the cost of
undertaking a protocol.
The designs presented in this article do not use adap-
tive randomisation methods (other than ceasing accrual
to some research arms and initiating new research arms)
as deployed in other multi-arm early phase trials.2,3 The
reasons for this are as follows. First, and perhaps most
importantly, there are conflicting views on whether
adapting the randomisation ratio actually achieves the
gains some have claimed,27 particularly in situations
where a lack of benefit analysis is already planned.
Second, in protocols where the intermediate and final
outcome measures are different, the intermediate out-
come measure is used only as a screen to reject research
arms which are unlikely to be effective on the final out-
come measure, not as means of assessing whether a
research treatment is clinically more effective. In this
situation, it would be inappropriate to weight the ran-
domisation based on an interim analysis on the inter-
mediate outcome measure. Finally, it is complex and
challenging to implement and explain adaptive rando-
misation methods in large-scale multi-centre rando-
mised late phase trials. Given the lack of clear benefits
and these challenges, we have not used them in any of
our late phase randomised trials.
Our aim in this research programme is to change the
fundamental goal of a single clinical protocol from the
typical two-arm randomised trial of ‘testing a new treat-
ment’ to ‘testing many treatments and hence improving
outcomes as rapidly as possible’. Clearly, not all trials
can run in this way. Nevertheless, in situations where
(a) there are a number of new therapies that might be
tested, (b) the same therapies may be used in multiple
related diseases and/or (c) there is sub-categorisation of
a single disease into subgroups who might benefit from
different new therapies, there is real need to change
how we think about a single protocol.
We are exploring opportunities to develop such pro-
tocols in areas, such as Alzheimer’s disease, multiple
sclerosis, HIV prevention, hepatitis C and wound heal-
ing, to speed the process of testing new therapies, and
we urge others involved in the design of new trials to
follow this way of thinking.
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